Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breath test could revolutionize childhood asthma management

NCT ID NCT07788534

Diagnosis Sponsor: King Faisal Specialist Hospital & Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study investigates whether using a breath test that measures airway inflammation (FeNO) can improve asthma management in children aged 6 to 14. Researchers will compare outcomes in children whose care includes regular FeNO monitoring against a similar group from the past who received standard care. The goal is to see if this additional test helps better control asthma symptoms and improve overall lung health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FeNO (fractional exhaled nitric oxide) test - a breath test measuring airway inflammation
What this could lead to
If successful, this could establish FeNO monitoring as a standard tool in pediatric asthma care, leading to better disease control and fewer symptoms for children.
What could go wrong
This is an observational study with a historical control group, which may introduce bias. The results may not be conclusive, and the test's benefit over standard care remains to be proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 6 to 14 years with a physician-diagnosed asthma. * Minimum of three months' follow-up at the pediatric respiratory clinic. * Availability of Asthma Control Test (ACT/C-ACT) scores and clinical data Exclusion Criteria: * Presence of other chronic pulmonary diseases (e.g., cystic fibrosis). * Recent respiratory infections within four weeks prior to enrollment. * Current treatment with biologic agents affecting asthma inflammation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma childhood onset asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma childhood

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King Faisal Sepiclaized Hospital and Research Center

    ACTIVE_NOT_RECRUITING

    Jeddah, Mecca Region, Saudi Arabia

  • king Faisal specialized hospital and research center

    RECRUITING

    Jeddah, Western Region, 21499, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.